

Doc#: 291305.1
LMT/SAB/hw
February 6, 2003



69011645
PATENT APPLICATION
DOCKET NO.: 2825.2026-001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Pamela Sklar, Eric S. Lander, J. Raymond DePaulo, Jr., and Melvin G. McInnis
Application No.: 10/077,171 Group Art Unit: 1645
Confirmation No.: 3181 Examiner: Not Assigned
Filed: February 15, 2002
Title: BDNF POLYMORPHISM AND ASSOCIATION WITH BIPOLAR DISORDER

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202	
on <u>2-6-03</u>	<u>Hollie Wakefield</u>
Date	Signature
HOLLIE WAKEFIELD	
Typed or printed name of person signing certificate	

RECEIVED
FEB 13 2003
TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references AA through AD, AL through AN, and AR through AU2 are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☒ Some of the listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

☐ Applicants request that the following non-published pending applications be considered:

Examiner's
Initials

____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []
____ U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

- ☐ A copy of each above-cited application, including the current claims, is enclosed.
- ☐ A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

- ☐ A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.
- ☐ Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.
- ☒ Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,


HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By Lisa M. Treannie
Lisa M. Treannie
Registration No.: 41,368
Telephone: (978) 341-0036
Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

2/6/03

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2825.2026-001		APPLICATION NO. 10/077,171	
		APPLICANT Pamela Sklar <i>et al.</i>		CONFIRMATION NO. 3181	
		FILING DATE February 15, 2002		GROUP 1645	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	
	AA	5,235,043	10-Aug-1993	Collins <i>et al.</i>	
	AB	5,606,031	25-Feb-1997	Lile <i>et al.</i>	
	AC	5,986,070	16-Nov-1999	Collins <i>et al.</i>	
	AD	6,458,541 B1	01-Oct-2002	Sklar <i>et al.</i>	
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	
	✓ AL	0 450 386 A2	9-Oct-1991	EPO	
	✓ AM	EP 1001037A2	17-May-00	EPO	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
✓	AR	Krebs, M. O. <i>et al.</i> , "Association Study of Brain-Derived Neurotrophic Factor (BDNF) Polymorphism in Schizophrenia," <i>Am. J. Med. Genet.</i> , 81(6):520 (1998)			
✓	AS	Leibrock, Joachim <i>et al.</i> , "Molecular cloning and expression of brain-derived neurotrophic factor," <i>Nature</i> , 341:149-152 (1989)			
✓	AT	Maisonpierre, Peter C. <i>et al.</i> , "Neurotrophin-3: A Neurotrophic Factor Related to NGF and BDNF," <i>Science</i> , 247:1446-1451 (1990)			
✓	AU	Hofer, Magdalena <i>et al.</i> , "Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain," <i>The EMBO Journal</i> , 9(8):2459-2464 (1990)			
✓	AV	Maisonpierre, Peter C. <i>et al.</i> , "Human and Rat Brain-Derived Neurotrophic Factor and Neurotrophin-3: Gene Structures, Distributions, and Chromosomal Localizations," <i>Genomics</i> , 10:558-568 (1991)			
✓	AW	Vicente, F.M. <i>et al.</i> , "Association between the BDNF gene and Schizophrenia," <i>Abstracts Society for Neuroscience</i> , 26th Annual Meeting, Washington, D.C., 22(1):96.15 Abstract			
✓	AX	Egan, M.F. <i>et al.</i> , "Effect of BDNF met66val Genotype on Verbal Memory and Risk for Schizophrenia," ScholarOne, Inc., 2001 [online], [retrieved on 2002-02-05]. Retrieved from the internet <URL:http://www.sfn.scholarone.com/itin2001/main.html?new_page_id=126&abstract_id=15698&is_...]			
EXAMINER			DATE CONSIDERED		

 RECEIVED
 FEB 13 2003
 TECH CENTER 1600/2900

PTO-1449 REPRODUCED

ATTORNEY DOCKET NO.
2825.2026-001APPLICATION NO.
10/077,171INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

February 6, 2003

(Use several sheets if necessary)

APPLICANT
Pamela Sklar *et al.*FILING DATE
February 15, 2002CONFIRMATION NO.
3181GROUP
1645

U.S. PATENT DOCUMENTS

EXAM
INER
INI-
TIAL

DOCUMENT NUMBER

ISSUE DATE /
PUBLICATION DATERECEIVED
FEB 13 2003
TECH CENTER 1600129000

FOREIGN PATENT DOCUMENTS



		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
✓	AN	WO 01/11085 A2	15-Feb-01	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

✓	AY	Weinberger, D.R. <i>et al.</i> , "Evidence for a Genetic Interaction Between Comt (val158met) and BDNF (met66val) and Susceptibility for Schizophrenia," ScholarOne, Inc., 2001 [online], [retrieved on 2002-02-05]. Retrived from the internet <URL:http://www.sfn.scholarone.com/itin2001/main.html?new_page_id=126&abstract_id=10589&is_...]
✓	AZ	Cronin, M.T. <i>et al.</i> , "Applying Rapid DNA Microarray Optimization Capability To SNP Screening And Genotyping," <i>American J. of Human Genetics</i> , 4(65):A244 (1999)
✓	AR2	Gerhold, David <i>et al.</i> , "DNA Chips: Promising Toys Have Become Powerful Tools," <i>Trends in Biochemical Sciences</i> , 24(5):168-173 (1999)
	AS2	McCarthy, Jeanette J. <i>et al.</i> , "The Use Of Single-Nucleotide Polymorphism Maps In Pharmacogenomics," <i>Nature Biotechnology</i> , 18:505-508 (2000)

EXAMINER

DATE CONSIDERED

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2825.2026-001		APPLICATION NO. 10/077,171			
		INFORMATION DISCLOSURE CITATION IN AN APPLICATION February 6, 2003 (Use several sheets if necessary)					
		APPLICANT Pamela Sklar et al.					
		FILING DATE February 15, 2002		CONFIRMATION NO. 3181	GROUP 1645		
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE		NAME		
							
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AT2	Sapolsky, Ronald J. et al., "High-throughput Polymorphism Screening and Genotyping with High-density Oligonucleotide Arrays," <i>Genetic Analysis: Biomolecular Engineering</i> 14:187-192 (1999)					
	AU2	Sklar, P. et al., "Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus," <i>Molecular Psychiatry</i> 7:579-593 (2002)					
EXAMINER		DATE CONSIDERED					